ライフサイエンスコーパス: tumor biopsy

1 h single cell DNA sequencing from a clinical tumor biopsy.

2 gram data could potentially be used to guide tumor biopsy.

3 ubclone that was not detected in the primary tumor biopsy.

4 ent-derived tumor organoids and the original tumor biopsy.

5 oregistered MR/PET images were used to guide tumor biopsy.

6 rofiling, detected by needle biopsy or solid tumor biopsy.

7 ery for complications arising from choroidal tumor biopsy.

8 egulated in human PCa cell lines and primary tumor biopsies.

9 in both murine xenografts and human ovarian tumor biopsies.

10 was used to assess the oxygenation status in tumor biopsies.

11 isms of acquired resistance to crizotinib in tumor biopsies.

12 e in both tumor cell lines and in metastatic tumor biopsies.

13 tic arrest or slippage, were assessed in the tumor biopsies.

14 tumor genotype; and signaling inhibition in tumor biopsies.

15 a or prior chemotherapy, and did not require tumor biopsies.

16 e study drug; nine patients underwent paired tumor biopsies.

17 age-specific molecular signatures on primary tumor biopsies.

18 d primarily in the glioblastoma cells in the tumor biopsies.

19 a subset of matched pre- and post-treatment tumor biopsies.

20 orrelated with the Ki-67 labeling index from tumor biopsies.

21 and metastatic human breast cancer cells and tumor biopsies.

22 human colorectal cancer cell lines and colon tumor biopsies.

23 as well as in some primitive neuroectodermal tumor biopsies.

24 n from sorted nuclei from fixed and archived tumor biopsies.

25 Five patients underwent tumor biopsies.

26 paclitaxel on the cell cycle through serial tumor biopsies.

27 10 needle biopsies of normal liver and four tumor biopsies.

28 This was also the case for 3 of 4 tumor biopsies.

29 umor cell lines, GBM stem cells, and primary tumor biopsies.

30 modulation and DNA damage response in paired tumor biopsies.

31 ed histone H2AX (gammaH2AX) levels in paired tumor biopsies.

32 e expression signature in NPC cell lines and tumor biopsies.

33 ting were performed on samples from mandated tumor biopsies.

34 ntly with miR-18a expression in human breast tumor biopsies.

35 tumor-infiltrating T cells in corresponding tumor biopsies.

36 d in CTCs and compared with those present in tumor biopsies.

37 mutations within the ALK kinase domain from tumor biopsies.

38 cer genome of individual patients from small tumor biopsies.

39 d by many somatic mutations found in primary tumor biopsies.

40 Eight of 28 tumor biopsies (28.6%) were pHER2+ by enzyme-linked immu

41 OSM is expressed in glioblastoma multiforme tumor biopsies, a particularly malignant form of brain t

42 Microtubule stabilization occurred in tumor biopsies after treatment with ixabepilone.

43 Tumor biopsy analyses from a synovial sarcoma patient tr

44 Tumor biopsy analysis revealed a significant increase in

45 Sequential tumor biopsy analysis revealed that bMMRD/polymerase-mut

46 iven that both TMA tissue cores and clinical tumor biopsies analyze only a small fraction of the tumo

47 amplifications of the POU2F2 locus in DLBCL tumor biopsies and a recurrent mutation of threonine 223

48 Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53,

49 as tested employing repeated sampling within tumor biopsies and changes in reagent lots.

50 e of copy-number heterogeneity assessment in tumor biopsies and circulating tumor DNA detection in pl

51 Tumor DNA from pretreatment tumor biopsies and control DNA from paired normal surgic

52 Tumor biopsies and dynamic contrast-enhanced magnetic re

53 pression profiles in pre- and post-treatment tumor biopsies and evaluated the effect of cediranib on

54 nt COO calls in 96% of 49 repeatedly sampled tumor biopsies and in 100% of 83 FFPET biopsies tested a

55 yzed whole exomes from pretreatment melanoma tumor biopsies and matching germline tissue samples from

56 of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at

57 Therefore, we first examined tumor biopsies and plasma of patients with metastatic RC

58 ately up-regulated on blood vessels in human tumor biopsies and play critical roles in angiogenesis,

59 ty (ITH) is emerging, both within individual tumor biopsies and spatially separated between biopsies

60 peared to be down-regulated or absent in the tumor biopsies and tumor cell lines examined.

61 P = .03-.001) between methylation levels in tumor biopsy and gastric washes.

62 ons for clinical trial design to incorporate tumor biopsy and molecular characterization to develop b

63 All the tumor biopsies, and nearly all primary cell mesothelioma

64 cted by immunohistochemistry in pretreatment tumor biopsies, and scored independently by 2 investigat

65 cted by immunohistochemistry in pretreatment tumor biopsies, and scored independently by 2 investigat

66 ts underwent pretreatment and post-treatment tumor biopsies, and tissues were analyzed for acetylated

67 Bona fide CSC purified from tumor biopsies are limited in supply and this hampers st

68 equivalent to those in malignant astrocytic tumor biopsies as assessed by Western blot analysis.

69 MAGE1A CpG island in PBCs, buccal cells, and tumor biopsies, as well as elevation of HbF expression.

70 ng BUdR were determined in rectal mucosa and tumor biopsies at the end of the first BUdR infusion (da

71 125) plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test resu

72 Sixteen patients had tumor biopsies before and 1 week after therapy; genomic

73 er cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with

74 Tumor biopsies before and during treatment were evaluate

75 ampling at baseline, week 2, and week 4 with tumor biopsies before treatment and at week 4.

76 hylomic analysis of patient-matched melanoma tumors biopsied before therapy and during disease progre

77 cancer progression can be predicted in human tumor biopsies by abundant hyaluronan (HA) and its proce

78 ion of frozen sections from 10 primary brain tumor biopsies by immunohistochemistry revealed expressi

79 levels in aggressive metastatic human breast tumor biopsies compared with normal breast tissues.

80 -regulated on the brain MvEC in glioblastoma tumor biopsies compared with the normal brain.

81 We found that 9 of 10 head and neck tumor biopsies contained a subpopulation of cells that e

82 rs are specifically cytotoxic to human colon tumor biopsy cultures as well as colon cancer cell lines

83 Paired tumor biopsies demonstrated reduced ERK phosphorylation

84 Tumor biopsies demonstrated T-cell infiltration after th

85 p53 expression was detected in tumor biopsies despite antibody responses after Ad-p53 i

86 Clinically, analysis of human aRMS tumor biopsies documented high PLK1 expression to offer

87 ve technique lends itself to samples such as tumor biopsies, dried blood spots and fluids including u

88 From pretherapeutic endoscopic tumor biopsies, ERCC1 rs11615 single-nucleotide polymorp

89 imultaneously elucidates the complexity of a tumor biopsy, estimating cancerous cell purity, tumor pl

90 ng-based strategies, which focus on a single tumor biopsy, fail to take into account intratumoral het

91 HSP27 protein levels were increased in tumor biopsies following treatment of patients with 17AA

92 Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression befor

93 ed colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based

94 improved technologies for rapidly genotyping tumor biopsies for relevant lesions, the implementation

95 tic RCC for levels of CXCR2 ligands, and RCC tumor biopsies for the expression of CXCR2.

96 Patients were required to have a dedicated tumor biopsy for determination of RRM1 and ERCC1 gene ex

97 rwent transretinal or transscleral choroidal tumor biopsy for diagnostic or prognostic purposes betwe

98 All patients underwent tumor biopsy for GEP prognostic testing.

99 ma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping.

100 les were obtained from pretreatment core-cut tumor biopsies from 104 postmenopausal patients with pri

101 Ninety lymph nodes (LN) and their primary tumor biopsies from 11 esophago-gastrectomy specimens we

102 p16 were analyzed by using paraffin-embedded tumor biopsies from 143 anal carcinomas.

103 By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients trea

104 Sequential tumor biopsies from 33 patients were examined.

105 s, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with >/=10% cfDNA tumor

106 nscriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected indiv

107 Using tumor biopsies from BRAF(V600E) melanoma patients treate

108 ression of CYP17A1 was markedly increased in tumor biopsies from CRPC patients after CYP17A1 inhibito

109 eal-time polymerase chain reaction on paired tumor biopsies from eight patients demonstrated downregu

110 ast cancer cells, as well as in human breast tumor biopsies from infiltrating carcinomas, suggesting

111 Interestingly, HRG expression in tumor biopsies from invasive breast carcinomas (n = 189)

112 Recent findings in tumor biopsies from lung adenocarcinoma patients suggest

113 S, human lung adenocarcinoma cell lines, and tumor biopsies from lung adenocarcinoma patients.

114 Analysis of tumor biopsies from patients with BRAF-mutant melanoma p

115 arcinoma, and glioblastoma cell lines and by tumor biopsies from patients with colorectal carcinomas,

116 A subset of tumor biopsies from patients with disease progression de

117 nfirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing b

118 rresponding Ki67, GLUT1, pS6RP expression in tumor biopsies from patients with head and neck cancer.

119 demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus

120 Four of 10 paired tumor biopsies from PTC patients showed a reduction in l

121 that ADM and AHR were coupregulated in lung tumor biopsies from smoker patients.

122 In breast tumor biopsies from women diagnosed with BrCA we found t

123 FR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patient with acquired erlotinib resi

124 nostic evaluation of soft tissue sarcomas is tumor biopsy, functional imaging techniques is growing a

125 Analysis of LMP1 genes isolated from tumor biopsies has revealed considerable sequence variat

126 hemical analyses from pre- and posttreatment tumor biopsies have been used as an efficacy end point f

127 ly assess clinically actionable mutations in tumor biopsies in a cost-effective manner.

128 rations involved in performing nondiagnostic tumor biopsies in competent adults for research purposes

129 0 in peripheral-blood mononuclear cells, and tumor biopsies in patients at the maximum-tolerated dose

130 Marked TIL and/or PBL could be detected in tumor biopsies in six of nine patients as early as day 6

131 d expression of cadherin-11 protein in human tumor biopsies in three out of seven patients examined a

132 as originally inferred from studies of human tumor biopsies in which a positive correlation was seen

133 We performed whole-exome sequencing of 98 tumor biopsies including complex atypical hyperplasias,

134 umors, we analyzed a panel of 19 human brain tumor biopsies, including glioblastomas.

135 terotransplantation of human cancer cells or tumor biopsies into immunodeficient rodents (xenograft m

136 ensitivity of conventional DNA sequencing in tumor biopsies is limited by stromal contamination and b

137 he genome-wide concordance between cfDNA and tumor biopsies is uncertain.

138 rognostic information gained by preoperative tumor biopsy is being investigated.

139 Vitrectomy for complications of choroidal tumor biopsy is rare.

140 An exploratory analysis of pretreatment tumor biopsies led to defining PD-L1-positive as >/= 25%

141 l as from aggressive metastatic human breast tumor biopsies localized primarily in and around the nuc

142 e significantly, in an analysis of 35 breast tumor biopsies, mammaglobin mRNA levels were increased a

143 EBV-specific CTLs were detected in tumor biopsy material obtained from 3 of 6 of the patien

144 bled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader

145 biotin nick-end labeling (TUNEL) staining in tumor biopsies (n = 15).

146 Immunohistochemical evaluation of melanoma tumor biopsies (n = 242) revealed two distinct patient p

147 Using fresh human breast tumor biopsies (N = 60 patients), we observed through mu

148 Tumor biopsies obtained after treatment showed tumor-sel

149 rowth and survival pathways were assessed in tumor biopsies obtained before and after 21 days of ther

150 ys in escalating dose cohorts, with skin and tumor biopsies obtained before and after dosing.

151 nsive cells and was also readily detected in tumor biopsies obtained before the establishment of the

152 The predictor was applied to tumor biopsies obtained from a Phase II clinical trial.

153 l cell infection and transgene expression in tumor biopsies of diverse histologies.

154 In addition, the primary tumor biopsies of HL-affected relatives were collected w

155 at organoid cultures can be established from tumor biopsies of patients with metastatic colorectal ca

156 ttern of the human androgen receptor gene in tumor biopsies of women with KS.

157 Tumor biopsy of 13 adult patients yielded 16 enhancing a

158 or crizotinib treatment is currently done on tumor biopsies or fine-needle aspirations.

159 Tumor biopsies or malignant ascites were collected from

160 those with tumor mass >3 cm, transperitoneal tumor biopsy, or metastatic disease) or with a prior mal

161 d acetylated alpha-tubulin were increased in tumor biopsies performed after ixabepilone therapy.

162 Tumor biopsies pretherapy and 2 and 4 weeks after gene i

163 Performing nondiagnostic tumor biopsies raises technical and ethical concerns mos

164 ary evaluation of Cyr61 expression in breast tumor biopsies revealed expression of Cyr61 in about 30%

165 Immunohistochemical analysis of paired tumor biopsies revealed increased nuclear accumulation o

166 dition, sampling of spatially distinct colon tumor biopsies revealed pTyr differences as dramatic as

167 Genomic analysis of tumor biopsies revealed that vismodegib resistance is as

168 expression of GRM1/mGluR1 in a number of RCC tumor biopsy samples and cell lines, and the effects of

169 evels were high in 153 of 339 human prostate tumor biopsy samples examined and detectable in only 2 o

170 clonal diversity that is captured in single tumor biopsy samples represents only a small proportion

171 Evidence from tumor biopsy samples shows that expression levels for ge

172 We analyzed ISEL tumor biopsy samples to examine relationships between bi

173 Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate,

174 on of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma

175 and CHOP was noted in hypoxic areas of human tumor biopsy samples.

176 infection previously observed in a subset of tumor biopsy samples: the persistence of het DNA in the

177 ction in PAR levels was observed in 3 paired tumor biopsy samples; a greater than 50% reduction was o

178 mor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to

179 trategies that depend on results from single tumor-biopsy samples.

180 Tumor biopsies showed decreases in cell-signaling pathwa

181 of 28 mg/m(2) before plateauing, and paired tumor biopsies showed nuclear accumulation of key tumor-

182 Analysis of fibrin expression in human tumor biopsies showed significant fibrin staining in nea

183 The feasibility study in paired human tumor biopsies showed that this biomarker can be reliabl

184 percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient out

185 because of its regional separation from the tumor biopsy site.

186 The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence o

187 ogen/progesterone receptor expression by the tumor biopsy specimen.

188 EGFr immunostaining was performed on 76 tumor biopsy specimens (86%), and 69 (91%) scored positi

189 ) either in vitro cultures of ChHV5-positive tumor biopsy specimens (plugs) or organotypic cultures (

190 CNT1 expression was lower in tumor biopsy specimens from Alb-SV40 rat livers than in

191 itor resistance was additionally observed in tumor biopsy specimens from patients treated with these

192 Tumor biopsy specimens from previously untreated patient

193 in platinum-sensitive and platinum-resistant tumor biopsy specimens from six patients with BRCA germl

194 method is currently being applied to analyze tumor biopsy specimens in early-phase clinical trials.

195 PC6 and -7 genomes, which were isolated from tumor biopsy specimens of advanced metastatic NPC cases,

196 Biomarkers were measured in tumor biopsy specimens taken at baseline, and after 2 an

197 All tumor biopsy specimens were obtained within 6 weeks of t

198 gression and regression were assessed in BCC tumor biopsy specimens.

199 Tumor-biopsy specimens from 303 patients with aggressive

200 We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop

201 When T790M was detectable in pretreatment tumor-biopsy specimens, the presence of the mutation cor

202 olated free plasma DNA and from the original tumor-biopsy specimens.

203 s of rh-Endo on endothelial cells within the tumors, biopsy specimens of tumor tissue were obtained b

204 a(v)beta3-expressing melanoma cells in human tumor biopsies, suggesting that alpha(v)beta3 interactio

205 CD8(+) tumor-infiltrating lymphocytes in the tumor biopsies taken at the same time points, as well as

206 Analysis of 16 paired tumor biopsies taken before and after development of cli

207 ifferential DNA copy number between multiple tumor biopsies that correlated with altered expression o

208 human Ig in the sera of mice inoculated with tumor biopsy tissue are associated with the growth arres

209 tation of small pieces of human primary lung tumor biopsy tissue into SCID mice results in a viable s

210 ondisrupted 1-mm3 pieces of fresh human lung tumor biopsy tissue into the subcutis of severe combined

211 implanting nondisrupted pieces of human lung tumor biopsy tissues into SCID mice, it has been possibl

212 GSH was depleted in sequential tumor biopsies to a variable extent, but with a similar

213 Pretreatment tumor biopsies to assess topoisomerase-I (Topo-I) activi

214 immunofluorescent analyses of 116 colorectal tumor biopsies to determine levels of EGFR in tumor and

215 Tumor biopsies to identify T790M were performed during s

216 ly members in prostate cancer cell lines and tumor biopsies to identify which members might be most a

217 nalysis, we prospectively analyzed available tumor biopsies to investigate the relationship between b

218 s and whole exomes were sequenced in relapse tumor biopsies to search for molecular correlates, and t

219 h T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M.

220 of the infiltrating lymphocytes in skin and tumor biopsies using T cell-specific peptide-major histo

221 A wide variety of tumor biopsies was profiled, showing for the first time

222 In selected patients, tumor biopsy was performed before and during treatment t

223 Across multiple mouse tumor models and human tumor biopsies, we have delineated the intratumoral dend

224 arge-scale genomic data sets of solid tissue tumor biopsies, we quantified the cytolytic activity of

225 Four patients' tumor biopsies were assessable for immunohistochemistry

226 Tumor biopsies were assessed for accumulation of mitotic

227 PBMCs and matched tumor biopsies were collected 24 h before (i.e., baselin

228 omes of pharmacodynamic assays from skin and tumor biopsies were concordant in several patients.

229 The copy number variations in the subsequent tumor biopsies were concordant with the NIPT plasma GR p

230 A minimum of 1,873 tumor biopsies were documented in the 72 studies, 12 of

231 quantitative polymerase chain reaction, and tumor biopsies were examined by immunohistochemistry for

232 ning or immunoblotting, SCCHN cell lines and tumor biopsies were examined for the presence of the com

233 Pretreatment tumor biopsies were immunohistochemically characterized

234 Changes in HSPs and client proteins in tumor biopsies were not consistent between baseline and

235 Patient tumor biopsies were obtained and stained immunohistochem

236 At the MTD, paired tumor biopsies were obtained at baseline and after the f

237 In this study tumor biopsies were obtained from 14 patients with metas

238 Serial tumor biopsies were obtained from consenting patients wh

239 Fresh tumor biopsies were obtained in cohort 1 to assay for ph

240 Blood samples and tumor biopsies were obtained pre- and postdrug administr

241 Tumor biopsies were obtained, if possible, before and du

242 Tumor biopsies were performed after the first gemcitabin

243 eukocytes, pre- and 24 hours post-treatment, tumor biopsies were performed and demonstrated target in

244 Tumor biopsies were performed before and after completio

245 Serial tumor biopsies were performed when possible and analyzed

246 Diagnostic tumor biopsies were reviewed by the European Mantle Cell

247 n peripheral mononuclear cells (PMN), and in tumor biopsies when available, at intervals following BS

248 suggest that the AH can serve as a surrogate tumor biopsy when Rb tumor tissue is not available.

249 f the HPV-negative tumor cells grew from the tumor biopsies, whereas five of seven (71%) of the HPV-p

250 vity correlates with degraded pericentrin in tumor biopsies, whereas normal tissues exhibit intact pe

251 he study of primary human specimens, such as tumor biopsies, which are heterogeneous and of finite qu

252 solate the nuclei of clonal populations from tumor biopsies, which was coupled with array CGH and tar

253 re represented in >20% of the alleles of the tumor biopsy with >90% sensitivity and approximately 100

254 f modified forms of histone H4 expression in tumor biopsies would be helpful in management of patient

255 hypothesized that profiles derived from lung tumor biopsies would discriminate tumor-specific gene si